| Literature DB >> 21850186 |
Teresa Nieto-Miguel1, Margarita Calonge, Ana de la Mata, Marina López-Paniagua, Sara Galindo, María Fideliz de la Paz, Rosa M Corrales.
Abstract
PURPOSE: Corneal epithelium is maintained by a population of stem cells (SCs) that have not been identified by specific molecular markers. The objective of this study was to find new putative markers for these SCs and to identify associated molecular pathways.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21850186 PMCID: PMC3156782
Source DB: PubMed Journal: Mol Vis ISSN: 1090-0535 Impact factor: 2.367
Oligonucleotide primers and probes used for real time PCR
| Glyceraldehyde-3-phosphate dehydrogenase | 4352934E | |
| Protein p63 | Hs00978338_m1 | |
| ATP-binding cassette, sub-family G, member 2 | Hs00184979_m1 | |
| Keratin 3 | Hs00365080_m1 | |
| Keratin 5 | Hs00361185_m1 | |
| Keratin 7 | Hs00818825_m1 | |
| Keratin 12 | Hs00165015_m1 | |
| Keratin 14 | Hs00559328_m1 | |
| Keratin 15 | Hs00267035_m1 | |
| Keratin 19 | Hs01051611_gh |
*Identification number from Applied Biosystems (www.appliedbiosystems.com).
Figure 1Relative expression of cytokeratins (KRTs), p63, and ABCG2 genes. Real time PCR was performed in 24 samples of limbal and corneal epithelial cells. Mean mRNA expression in limbal epithelial cells was expressed relative to that corneal epithelial cells. Positive values indicated relatively greater expression in limbal cells, while negative values indicated relatively less expression in limbal. Significance was analyzed by Student’s t-test. *p<0.05, **p<0.001, ***p<0.00001.
Up- and down-regulated genes in cells of the limbal epithelial stem cell niche.
| Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) | Extracellular space | Cytokine | +26.45 | |
| ISL LIM homeobox 1 | Nucleus | Transcription regulator | +20.90 | |
| Collagen, type II, alpha 1 | Extracellular space | Other | +19.47 | |
| Neural cell adhesion molecule 1 | Plasma membrane | Other | +11.82 | |
| ATP-binding cassette, sub-family G (WHITE), member 2 | Plasma membrane | Transporter | +10.25 | |
| Keratin 15 | Cytoplasm | Other | +10.00 | |
| Aggrecan | Extracellular space | Other | +9.24 | |
| Forkhead box A2 | Nucleus | Transcription regulator | +9.24 | |
| Gap junction protein, beta 1, 32 kDa | Plasma membrane | Transporter | +9.24 | |
| Msh homeobox 1 | Nucleus | Transcription regulator | +9.24 | |
| CD8b molecule | Plasma membrane | Other | +9.17 | |
| Desert hedgehog homolog (Drosophila) | Extracellular space | Peptidase | −17.66 | |
| Cell division cycle 2, G1 to S and G2 to M | Nucleus | Kinase | −9.33 | |
| Gap junction protein, alpha 1, 43 kDa | Plasma membrane | Transporter | −6.89 | |
| Cyclin A2 | Nucleus | Other | −6.71 | |
| Par-6 partitioning defective 6 homolog alpha (C. elegans) | Plasma membrane | Other | −5.13 | |
| K(lysine) acetyltransferase 2A | Cytoplasm | Enzyme | −5.07 | |
| Dishevelled, dsh homolog 1 (Drosophila) | Cytoplasm | Other | −4.61 | |
| Jagged 1 (Alagille syndrome) | Extracellular space | Growth factor | −4.54 | |
| S100 calcium binding protein B | Cytoplasm | Other | −4.34 | |
| Frequently rearranged in advanced T-cell lymphomas | Cytoplasm | Other | −4.28 |
Genes with higher (+) and lesser (-) expression in limbal epithelial cells compared to terminally differentiated corneal epithelial cells. Fold change was calculated by PCR array using the comparative Ct method. *Indicates cellular location where protein is expressed.
Ingenuity canonical pathways that were most significantly affected.
| Wnt/β2-catenin Signaling | 8.54E+00 | 6.67E-02 | SOX2, CDH2, GJA1, AXIN1, FRAT1, DVL1, BTRC, FZD1, CCND1, WNT1, APC |
| Notch Signaling | 3.28E+00 | 9.76E-02 | NOTCH2, DLL1, DTX1, JAG1 |
| Cell Cycle: G1/S Checkpoint Regulation | 2.58E+00 | 6.78E-02 | CCNE1, HDAC2, BTRC, CCND1 |
| Actin Cytoskeleton Signaling | 1.49E+00 | 2.20E-02 | FGF4, CDC42, ACTC1, APC, FGF1 |
| Aryl Hydrocarbon Receptor Signaling | 1.34E+00 | 2.58E-02 | CCNA2, CCNE1, ALDH1A1, CCND1 |
| Clathrin-mediated Endocytosis | 1.34E+00 | 2.42E-02 | FGF4, CDC42, ACTC1, FGF1 |
| Axonal Guidance Signaling | 1.34E+00 | 1.52E-02 | CDC42, BMP2, FZD1, WNT1, BMP1 |
| FGF Signaling | 1.27E+00 | 3.49E-02 | FGF4, FGFR1, FGF1 |
| Ephrin Receptor Signaling | 1.27E+00 | 2.07E-02 | CDC42, AXIN1, CXCL12, FGF1 |
| T Cell Receptor Signaling | 1.11E+00 | 2.78E-02 | CD8A, CD3D, CD8B |
| Cell Cycle: G2/M DNA Damage Checkpoint Regulation | 1.07E+00 | 4.65E-02 | BTRC, CDC2 |
| Tight Junction Signaling | 8.86E-01 | 1.83E-02 | CDC42, ACTC1, PARD6A |
| NF-Κ°B Signaling | 8.86E-01 | 2.08E-02 | HDAC2, BMP2, BTRC |
| Calcium-induced T Lymphocyte Apoptosis | 8.21E-01 | 3.28E-02 | HDAC2, CD3D |
| Leukocyte Extravasation Signaling | 7.08E-01 | 1.55E-02 | CDC42, CXCL12, ACTC1 |
| BMP signaling pathway | 7.08E-01 | 2.50E-02 | BMP2, BMP1 |
| Regulation of Actin-based Motility by Rho | 7.08E-01 | 2.17E-02 | CDC42, ACTC1 |
| PTEN Signaling | 6.12E-01 | 2.02E-02 | CDC42, CCND1 |
| Fcγ3 Receptor-mediated Phagocytosis in Macrophages and Monocytes | 5.94E-01 | 1.92E-02 | CDC42, ACTC1 |
| CD28 Signaling in T Helper Cells | 4.92E-01 | 1.65E-02 | CDC42, CD3D |
| Cytotoxic T Lymphocyte-mediated Apoptosis of Target Cells | 4.92E-01 | 3.85E-02 | CD3D |
| Glucocorticoid Receptor Signaling | 4.92E-01 | 1.09E-02 | HSPA9, BGLAP, CD3D |
| Hepatic Fibrosis / Hepatic Stellate Cell Activation | 4.73E-01 | 1.48E-02 | FGFR1, FGF1 |
| Sonic Hedgehog Signaling | 4.34E-01 | 3.23E-02 | CDC2 |
| Ascorbate and Aldarate Metabolism | 4.12E-01 | 1.22E-02 | ALDH1A1 |
| Calcium Signaling | 3.39E-01 | 9.71E-03 | HDAC2, ACTC1 |
| Retinol Metabolism | 3.39E-01 | 1.56E-02 | ALDH1A1 |
| Integrin Signaling | 3.39E-01 | 1.01E-02 | CDC42, ACTC1 |
| Huntington’s Disease Signaling | 3.39E-01 | 8.62E-03 | HDAC2, HSPA9 |
| Histidine Metabolism | 3.39E-01 | 9.01E-03 | ALDH1A1 |
| GM-CSF Signaling | 3.39E-01 | 1.54E-02 | CCND1 |
| Activation of IRF by Cytosolic Pattern Recognition Receptors | 3.39E-01 | 1.37E-02 | ADAR |
| Macropinocytosis | 3.39E-01 | 1.43E-02 | CDC42 |
| CCR5 Signaling in Macrophages | 3.39E-01 | 1.16E-02 | CD3D |
| Neurotrophin/TRK Signaling | 3.39E-01 | 1.32E-02 | CDC42 |
| Caveolar-mediated Endocytosis | 3.39E-01 | 1.25E-02 | ACTC1 |
| PXR/RXR Activation | 3.39E-01 | 1.16E-02 | ALDH1A1 |
| LPS-stimulated MAPK Signaling | 3.39E-01 | 1.27E-02 | CDC42 |
| Bile Acid Biosynthesis | 3.39E-01 | 1.03E-02 | ALDH1A1 |
| Chemokine Signaling | 3.39E-01 | 1.30E-02 | CXCL12 |
| L2-alanine Metabolism | 3.39E-01 | 1.01E-02 | ALDH1A1 |
| VDR/RXR Activation | 3.39E-01 | 1.25E-02 | BGLAP |
| Butanoate Metabolism | 3.39E-01 | 7.75E-03 | ALDH1A1 |
| Pyruvate Metabolism | 3.39E-01 | 6.90E-03 | ALDH1A1 |
| CTLA4 Signaling in Cytotoxic T Lymphocytes | 3.39E-01 | 1.16E-02 | CD3D |
| TGF-β2 Signaling | 3.39E-01 | 1.16E-02 | BMP2 |
| Lysine Degradation | 3.39E-01 | 6.94E-03 | ALDH1A1 |
| Propanoate Metabolism | 3.39E-01 | 7.94E-03 | ALDH1A1 |
| Apoptosis Signaling | 3.39E-01 | 1.06E-02 | CDC2 |
| p53 Signaling | 3.39E-01 | 1.15E-02 | CCND1 |
| VEGF Signaling | 3.39E-01 | 1.05E-02 | ACTC1 |
| SAPK/JNK Signaling | 3.39E-01 | 1.08E-02 | CDC42 |
| Glycerolipid Metabolism | 3.39E-01 | 6.90E-03 | ALDH1A1 |
| Valine, Leucine and Isoleucine Degradation | 3.39E-01 | 9.35E-03 | ALDH1A1 |
| FXR/RXR Activation | 3.39E-01 | 1.00E-02 | FOXA2 |
| Glycolysis/Gluconeogenesis | 3.33E-01 | 7.09E-03 | ALDH1A1 |
| Nicotinate and Nicotinamide Metabolism | 3.33E-01 | 7.75E-03 | CDC2 |
| fMLP Signaling in Neutrophils | 3.03E-01 | 8.00E-03 | CDC42 |
| Arginine and Proline Metabolism | 3.01E-01 | 5.62E-03 | ALDH1A1 |
| PI3K/AKT Signaling | 3.00E-01 | 7.41E-03 | CCND1 |
| Protein Ubiquitination Pathway | 2.60E-01 | 4.95E-03 | BTRC |
| Inositol Phosphate Metabolism | 2.60E-01 | 5.78E-03 | CDC2 |
| B Cell Receptor Signaling | 2.54E-01 | 6.54E-03 | CDC42 |
| CXCR4 Signaling | 2.51E-01 | 6.10E-03 | CXCL12 |
| IL-8 Signaling | 2.51E-01 | 5.46E-03 | CCND1 |
| Tryptophan Metabolism | 2.51E-01 | 4.20E-03 | ALDH1A1 |
| RAR Activation | 2.51E-01 | 5.49E-03 | ALDH1A1 |
| Role of NFAT in Regulation of the Immune Response | 2.51E-01 | 5.38E-03 | CD3D |
| Fatty Acid Metabolism | 2.51E-01 | 5.29E-03 | ALDH1A1 |
| NRF2-mediated Oxidative Stress Response | 2.51E-01 | 5.46E-03 | ACTC1 |
| LPS/IL-1 Mediated Inhibition of RXR Function | 2.29E-01 | 5.05E-03 | ALDH1A1 |
*The p-value was calculated using the Benjamini-Hochberg (BH) method. The ratio was calculated as the number of genes in a given pathway that met the cutoff criteria, two in this case, divided by the total number of genes that made up the pathway.
Figure 2Wnt/β-catenin signaling pathway generated by Ingenuity Pathway Analysis (IPA). The IPA depicted the genes involved, their interactions, and the cellular and metabolic reactions that constituted the pathway. Colored molecules represented genes that appeared in the data set studied. Red and green molecules were up- and down-regulated, respectively, in limbal epithelial cells. Gray molecules did not meet the user defined cutoff of 2.
Molecules significantly associated with relevant functions and diseases.
| Cellular Development | 3.49E-13–1.53E-02 | 37 |
| Tissue Development | 3.61E-10–1.53E-02 | 31 |
| Organismal Development | 3.91E-09–4.75E-03 | 22 |
| Embryonic Development | 2.37E-08–1.53E-02 | 26 |
| Cell Death | 3.61E-08–1.53E-02 | 35 |
| Gene Expression | 2.67E-07–1.53E-02 | 32 |
| Cellular Assembly and Organization | 2.67E-07–1.53E-02 | 22 |
| Nervous System Development and Function | 2.67E-07–1.53E-02 | 29 |
| Cancer | 3.1E-07–1.53E-02 | 40 |
| Cellular Growth and Proliferation | 5.45E-07–1.53E-02 | 39 |
| Cell Morphology | 5.45E-07–1.53E-02 | 23 |
| Cell Cycle | 1.15E-06–1.53E-02 | 17 |
| Organ Development | 1.69E-06–1.36E-02 | 20 |
| Skeletal and Muscular Disorders | 3.01E-06–1.53E-02 | 11 |
| Renal and Urological Disease | 4.17E-06–1.36E-02 | 7 |
| Genetic Disorder | 5.66E-06–1.53E-02 | 39 |
| Developmental Disorder | 7.55E-06–1.53E-02 | 17 |
| Connective Tissue Development and Function | 4.09E-05–1.53E-02 | 21 |
| Skeletal and Muscular System Development and Function | 4.09E-05–1.5E-02 | 17 |
| Hematological System Development and Function | 8.41E-05–1.53E-02 | 18 |
| Hematopoiesis | 8.41E-05–1.53E-02 | 13 |
| Neurologic Disease | 1.35E-04–1.53E-02 | 27 |
| Lymphoid Tissue Structure and Development | 1.86E-04–1.53E-02 | 9 |
| Auditory and Vestibular System Development and Function | 2.51E-04–8.77E-03 | 5 |
| Cell-To-Cell Signaling and Interaction | 2.92E-04–1.53E-02 | 23 |
| Cellular Movement | 2.98E-04–1.53E-02 | 22 |
| Cellular Function and Maintenance | 3.24E-04–1.53E-02 | 14 |
| Cardiovascular System Development and Function | 3.82E-04–1.53E-02 | 14 |
| Hepatic System Disease | 3.82E-04–1.53E-02 | 14 |
| Reproductive System Disease | 5.45E-04–1.53E-02 | 19 |
| Gastrointestinal Disease | 5.48E-04–1.53E-02 | 21 |
| Tissue Morphology | 6.35E-04–1.53E-02 | 18 |
| Energy Production | 6.56E-04–6.56E-04 | 3 |
| Molecular Transport | 6.56E-04–1.53E-02 | 3 |
| Nucleic Acid Metabolism | 6.56E-04–1.53E-02 | 4 |
| Small Molecule Biochemistry | 6.56E-04–1.53E-02 | 9 |
| Organ Morphology | 1.04E-03–1.53E-02 | 13 |
| Tumor Morphology | 1.13E-03–1.53E-02 | 10 |
| Metabolic Disease | 1.33E-03–1.33E-03 | 3 |
| DNA Replication. Recombination. and Repair | 1.5E-03–1.53E-02 | 11 |
| Connective Tissue Disorders | 1.54E-03–7.79E-03 | 10 |
| Humoral Immune Response | 2.21E-03–3.6E-03 | 4 |
| Visual System Development and Function | 2.21E-03–7.79E-03 | 4 |
| Psychological Disorders | 2.25E-03–2.25E-03 | 6 |
| Infection Mechanism | 2.47E-03–9.23E-03 | 4 |
| Post-Translational Modification | 2.69E-03–1.53E-02 | 11 |
| Carbohydrate Metabolism | 2.81E-03–2.81E-03 | 5 |
| Lipid Metabolism | 2.81E-03–2.81E-03 | 3 |
| Drug Metabolism | 2.81E-03–1.53E-02 | 3 |
| Endocrine System Development and Function | 2.81E-03–1.53E-02 | 4 |
| Hair and Skin Development and Function | 3.04E-03–1.53E-02 | 6 |
| Reproductive System Development and Function | 3.45E-03–1.53E-02 | 4 |
| Hematological Disease | 5.19E-03–1.53E-02 | 8 |
| Cardiovascular Disease | 5.28E-03–5.28E-03 | 4 |
| Cell-mediated Immune Response | 6.31E-03–1.3E-02 | 5 |
| Organismal Injury and Abnormalities | 6.88E-03–6.88E-03 | 3 |
| Digestive System Development and Function | 7.14E-03–7.14E-03 | 3 |
| Organismal Survival | 7.53E-03–7.53E-03 | 12 |
| Hepatic System Development and Function | 8.76E-03–8.76E-03 | 2 |
| Respiratory System Development and Function | 8.76E-03–1.53E-02 | 3 |
| Antigen Presentation | 1.23E-02–1.23E-02 | 2 |
| Inflammatory Disease | 1.53E-02–1.53E-02 | 2 |
| Cell Signaling | 1.53E-02–1.53E-02 | 2 |
| Protein Trafficking | 1.53E-02–1.53E-02 | 2 |
| Vitamin and Mineral Metabolism | 1.53E-02–1.53E-02 | 2 |
| Renal and Urological System Development and Function | 1.53E-02–1.53E-02 | 2 |
| Auditory Disease | 1.53E-02–1.53E-02 | 1 |
| Cellular Compromise | 1.53E-02–1.53E-02 | 1 |
| Dermatological Diseases and Conditions | 1.53E-02–1.53E-02 | 1 |
| Immune Cell Trafficking | 1.53E-02–1.53E-02 | 1 |
| RNA Post-Transcriptional Modification | 1.53E-02–1.53E-02 | 1 |
*The p-value was calculated using the Benjamini-Hochberg (BH) method.
Figure 3Networks generated by IPA related to the development and the function of the auditory, vestibular, skeletal and muscular systems and to the cancer development. Auditory and vestibular system development and function, organ development, and cancer network (A), and cancer, connective tissue development and function, skeletal and muscular system development and function network (B) generated by IPA. The networks contained nodes composed of genes/gene products and edges that indicated a relationship between the nodes in the cellular and subcellular locations indicated. Classes of nodes were indicated by shape to represent different functionalities. Colored molecules represented genes that appeared in the data set studied. Red and green molecules were upregulated and down-regulated, respectively, in the limbal epithelial cells. Gray molecules did not meet the user defined cutoff of 2. White indicated the molecule was added from the IPKB.
Figure 4Networks generated by IPA related to drug metabolism, small molecule biochemistry and cell morphology and to cancer, cell cycle, skeletal and muscular disorders. Drug metabolism, small molecule biochemistry and cell morphology network (A), and cancer, cell cycle, skeletal and muscular disorders network (B) generated by IPA. The network contained nodes (gene/gene product) and edges (indicating a relationship between the nodes) showing the cellular/subcellular location as indicated. Function classes of nodes were indicated by shape to represent functional class. Colored molecules represented genes that appeared in the data set studied. Red and green molecules were upregulated and down-regulated, respectively, in limbal epithelial cells. Gray molecules did not meet the user defined cutoff of 2. White indicated the molecule was added from the IPKB.
Figure 5Customized gene network based upon the six most highly upregulated limbal epithelial cell genes. We explored possible functional relationships between the six highest upregulated limbal epithelial cells genes (in red) using the IPKB. Our customized pathway contained nodes composed of genes/gene products and edges that indicated a relationship between the nodes in the cellular and subcellular locations indicated. White indicates that the molecule was added from the IPKB.